Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Teva
Federal Trade Commission
Dow
AstraZeneca
Colorcon
Cerilliant
Farmers Insurance
Daiichi Sankyo
Merck

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,056,051

« Back to Dashboard

Which drugs does patent 9,056,051 protect, and when does it expire?

Patent 9,056,051 protects TARGINIQ and is included in one NDA.

This patent has nineteen patent family members in nine countries.
Summary for Patent: 9,056,051
Title:Abuse-resistant controlled-release opioid dosage form
Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
Inventor(s): Caruso; Frank S. (Colts Neck, NJ), Kao; Huai-Hung (Syosset, NY)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:14/205,204
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 9,056,051

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-001 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. ➤ Subscribe
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-002 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. ➤ Subscribe
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-003 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,056,051

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,283,216 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
8,969,369 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
9,358,230 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
9,084,729 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
9,283,221 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
9,168,252 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
9,161,937 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
9,511,066 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
9,345,701 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
9,480,685 Abuse-resistant controlled-release opioid dosage form ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,056,051

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2016222732 ➤ Subscribe
Japan 2009102405 ➤ Subscribe
Japan 6203782 ➤ Subscribe
Japan 2015155467 ➤ Subscribe
Japan 5977784 ➤ Subscribe
Japan 2014167033 ➤ Subscribe
Japan 5765820 ➤ Subscribe
Japan 2012246319 ➤ Subscribe
Japan 4522652 ➤ Subscribe
Japan 2005515152 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Queensland Health
Accenture
Cantor Fitzgerald
Chubb
Argus Health
Teva
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot